<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A mouse monoclonal antibody (MAb) against Epstein-Barr virus (EBV) envelope <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> 350, 72A1, inhibited <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> of B lymphocytes in vitro </plain></SENT>
<SENT sid="1" pm="."><plain>When severe combined immunodeficient mice were injected with EBV-seronegative donors' peripheral-blood mononuclear cells and challenged with EBV, 72A1 MAb prevented development of EBV-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>: none of the test mice (0/12) developed EBV-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, 67% (8/12) of control mice developed EBV-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (P=.001) </plain></SENT>
<SENT sid="3" pm="."><plain>Purified 72A1 MAb was infused into 1 healthy adult and 4 EBV-seronegative children after liver transplant </plain></SENT>
<SENT sid="4" pm="."><plain>No adverse reactions were seen in the adult or in 3 of the transplant recipients </plain></SENT>
<SENT sid="5" pm="."><plain>The remaining patient developed a hypersensitivity reaction, thus underlining the need to humanize the MAb </plain></SENT>
</text></document>